Aperio receives FDA approval for HER2 image analysis application

Twitter icon
Facebook icon
LinkedIn icon
e-mail icon
Google icon

Aperio Technologies, a digital pathology provider for the healthcare and life sciences industry, has received clearance from the U.S. FDA to market the HER2 image analysis application available through its ScanScope slide scanning system.

The FDA-cleared immunohistochemistry image analysis application can be used as an aid to pathologists in detecting and quantifying HER2 protein expression from digital slide images, according to the Vista, Calif.-based company.

Aperio’s digital pathology system and the specific image analysis application are included in the FDA clearance.